Vistagen Therapeutics 주식 (NASDAQ: VTGN)

에 대한 최신 뉴스 Vistagen Therapeutics (NASDAQ:VTGN) 주식

Vistagen Therapeutics

VistaGen Therapeutics

Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.

Vistagen Therapeutics, Inc. - Common Stock

Vistagen Therapeutics Inc

WIIM

BTBT

Bit Digital shares are trading lower after the company announced a public offering.

Linde (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIN#NASDAQ">LIN</a>) has outperformed the market over the past 20 years by 3.78% on an annualized basis producing an average annual return of 12.2%. Currently, Linde has a market capitalization of $217.63 billion. 
Buying $1000 In LIN: If an investor had bought $1000 of LIN stock 20 years ago, it would be worth $9,941.67 today based on a price of $460.20 for LIN at the time of writing.
<h3>Linde's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750882533_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today

H.B. Fuller shares are trading higher after the company raised its FY2025 Adj. EPS guidance.

MillerKnoll (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLKN#NASDAQ">MLKN</a>) reported quarterly earnings of $0.60 per share which beat the analyst consensus estimate of $0.44 by 37.3 percent. This is a 10.45 percent decrease over earnings of $0.67 per share from the same period last year. The company reported quarterly sales of $961.80 million which beat the analyst consensus estimate of $913.70 million by 5.26 percent. This is a 8.20 percent increase over sales of $888.90 million the same period last year.

Earnings

Earnings Beats

MLKN

MillerKnoll Q4 Adj. EPS $0.60 Beats $0.44 Estimate, Sales $961.80M Beat $913.70M Estimate

<a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1275158/000127515825000081/ndls-20250624.htm">https://www.sec.gov/ix?doc=/Archives/edgar/data/1275158/000127515825000081/ndls-20250624.htm</a>

General

NDLS

Noodles & Co Receives Nasdaq Non-Compliance Notice

MillerKnoll (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLKN#NASDAQ">MLKN</a>) is looking for Q1 Adj EPS of $0.32-$0.38 vs $0.35 analyst estimate. sees sales of $899.000 million-$939.000 million vs $890.70 million analyst estimate.

Guidance

MillerKnoll Sees Q1 Adj EPS $0.32-$0.38 vs $0.35 Est; Sees Sales $899.000M-$939.000M vs $890.70M Est

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

In March Bit Digital Held 24,434.2 ETH And 417.6 BTC Valued At $44.6M And $34.5M; Intends To Convert BTC Holdings Into ETH Over Time

Euroholdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EHLD#NASDAQ">EHLD</a>) reported quarterly earnings of $0.31 per share. This is a 42.59 percent decrease over earnings of $0.54 per share from the same period last year. The company reported $2.873 million in sales this quarter. This is a 24.91 percent decrease over sales of $3.826 million the same period last year.

EHLD

Euroholdings Q1 Adj. EPS $0.31 Down From $0.54 YoY, Sales $2.873M Down From $3.826M YoY

GKOS

Glaukos Announces EU MDR Certification For iStent infinite

MillerKnoll (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLKN#NASDAQ">MLKN</a>) reported quarterly earnings of $0.60 per share which beat the analyst consensus estimate of $0.44 by 37.3 percent. This is a 10.45 percent decrease over earnings of $0.67 per share from the same period last year.

MillerKnoll Q4 Adj. EPS $0.60 Beats $0.44 Estimate

H.B. Fuller Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUL#NYSE">FUL</a>) today reported financial results for its second quarter that ended May 31, 2025.
 Fiscal 2025 Outlook:
As a result of our strong financial performance, we are updating our previously communicated financial guidance for fiscal 2025 as follows:
<ul>
<li>Net revenue for fiscal 2025 is now expected to be down 2% to 3%; organic revenue for fiscal 2025 is still expected to be flat to up 2%; we now expect foreign exchange to adversely impact net revenue by 1.0% to 1.5%;</li>
<li>Adjusted EBITDA for fiscal 2025 is now expected to be in the range of $615 million to $630 million, equating to growth of 4% to 6% year-on-year;</li>
<li>Adjusted EPS (diluted) is now expected to be in the range of $4.10 to $4.30, equating to growth of 7% to 12% year-on-year;</li>
<li>Fully diluted shares outstanding for fiscal 2025 is now expected to be in the range of 55 million to 56 million;</li>
<li>Adjusted EBITDA for the third quarter of 2025 is expected to be in the range of $165 million to $175 million.</li>
</ul>

H.B. Fuller Now Expects FY25 Revenue To Be Down 2% - 3%; Now Sees FY25 Organic Revenue To Be Flat To Up 2%

Management

ASAN

Asana Appoints Dan Rogers As CEO, Effective July 21, 2025

Steelcase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCS#NYSE">SCS</a>) is looking for Q2 GAAP EPS of $0.27-$0.31 vs $0.39 analyst estimate..

Steelcase Sees Q2 GAAP EPS $0.27-$0.31 vs $0.39 Est

Steelcase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCS#NYSE">SCS</a>) is looking for Q2 Adj EPS of $0.36-$0.40 vs $0.40 analyst estimate. sees sales of $860.000 million-$890.000 million vs $878.80 million analyst estimate.

Steelcase Sees Q2 Adj EPS $0.36-$0.40 vs $0.40 Est; Sees Sales $860.000M-$890.000M vs $878.80M Est

Offerings

KYMR

Kymera Therapeutics Announces Proposed $250M Public Offering

H.B. Fuller (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUL#NYSE">FUL</a>) raises FY2025 Adj EPS guidance from $3.90-$4.20 to $4.10-$4.30 vs $4.08 analyst estimate..

H.B. Fuller Raises FY2025 Adj EPS Guidance from $3.90-$4.20 to $4.10-$4.30 vs $4.08 Est

RMCF

Rocky Mountain Chocolate Factory Regains Nasdaq Compliance

Steelcase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCS#NYSE">SCS</a>) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.13 by 50.38 percent. This is a 25 percent increase over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $779.00 million which beat the analyst consensus estimate of $762.42 million by 2.17 percent. This is a 7.11 percent increase over sales of $727.30 million the same period last year.

Steelcase Q1 Adj. EPS $0.20 Beats $0.13 Estimate, Sales $779.00M Beat $762.42M Estimate

H.B. Fuller (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUL#NYSE">FUL</a>) reported quarterly earnings of $1.18 per share which beat the analyst consensus estimate of $1.08 by 9.46 percent. This is a 5.36 percent increase over earnings of $1.12 per share from the same period last year. The company reported quarterly sales of $898.095 million which missed the analyst consensus estimate of $899.955 million by 0.21 percent. This is a 2.07 percent decrease over sales of $917.107 million the same period last year.

Earnings Misses

H.B. Fuller Q2 Adj. EPS $1.18 Beats $1.08 Estimate, Sales $898.095M Miss $899.955M Estimate

Bit Digital Announces Public Offering; Size Not Disclosed

Press Releases

Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference

Vistagen to Participate in Stifel 2025 Virtual CNS Forum

Vistagen to Present at the 2025 Anxiety and Depression Association Conference

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference

Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference

Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York

Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year

Comments

Vistagen Therapeutics

뉴스

에 대한 최신 뉴스 Vistagen Therapeutics (NASDAQ:VTGN) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌